Results 61 to 70 of about 606,957 (319)

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Automated Diagnosis of Lymphoma with Digital Pathology Images Using Deep Learning [PDF]

open access: yesarXiv, 2018
Recent studies have shown promising results in using Deep Learning to detect malignancy in whole slide imaging. However, they were limited to just predicting positive or negative finding for a specific neoplasm. We attempted to use Deep Learning with a convolutional neural network algorithm to build a lymphoma diagnostic model for four diagnostic ...
arxiv  

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

open access: yesMolecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS

open access: yesHemaSphere, 2022
R. Steiner   +13 more
doaj   +1 more source

Advances in the assessment of minimal residual disease in mantle cell lymphoma

open access: yesJournal of Hematology & Oncology, 2020
The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma.
Dayoung Jung   +3 more
doaj   +1 more source

A potential tumor suppressor role of PLK2 in glioblastoma

open access: yesFEBS Open Bio, EarlyView.
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia   +5 more
wiley   +1 more source

Information Preserving Component Analysis: Data Projections for Flow Cytometry Analysis [PDF]

open access: yes, 2008
Flow cytometry is often used to characterize the malignant cells in leukemia and lymphoma patients, traced to the level of the individual cell. Typically, flow cytometric data analysis is performed through a series of 2-dimensional projections onto the axes of the data set.
arxiv   +1 more source

Acacetin reduces endoplasmic reticulum stress through the P‐eNOS/PERK signaling pathway to attenuate MGO‐induced vascular endothelial cell dysfunction

open access: yesFEBS Open Bio, EarlyView.
We investigated a potential protective effect of acacetin, a naturally occurring flavonoid, against methylglyoxal (MGO)‐induced endothelial dysfunction in human umbilical vein endothelial cells and its mechanism of action. Acacetin can could inhibit MGO‐induced intracellular calcium ion influx, enhance the expression levels of phosphorylated ...
Zhen Zhang   +7 more
wiley   +1 more source

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

open access: yesFEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy